251 related articles for article (PubMed ID: 21822687)
1. Evaluation of bone markers in hypophosphatemic rickets/osteomalacia.
Nagata Y; Imanishi Y; Ishii A; Kurajoh M; Motoyama K; Morioka T; Naka H; Mori K; Miki T; Emoto M; Inaba M
Endocrine; 2011 Oct; 40(2):315-7. PubMed ID: 21822687
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic role of Fgf23 in Dmp1-null mice.
Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
[TBL] [Abstract][Full Text] [Related]
3. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice.
Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S
J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065
[TBL] [Abstract][Full Text] [Related]
4. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY
Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556
[TBL] [Abstract][Full Text] [Related]
5. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.
Yamazaki Y; Okazaki R; Shibata M; Hasegawa Y; Satoh K; Tajima T; Takeuchi Y; Fujita T; Nakahara K; Yamashita T; Fukumoto S
J Clin Endocrinol Metab; 2002 Nov; 87(11):4957-60. PubMed ID: 12414858
[TBL] [Abstract][Full Text] [Related]
6. Elevated Bone Remodeling Markers of CTX and P1NP in Addition to Sclerostin in Patients with X-linked Hypophosphatemia: A Cross-Sectional Controlled Study.
Hansen S; Shanbhogue VV; Jørgensen NR; Beck-Nielsen SS
Calcif Tissue Int; 2019 Jun; 104(6):591-598. PubMed ID: 30710161
[TBL] [Abstract][Full Text] [Related]
7. Mineralized tissues in hypophosphatemic rickets.
Robinson ME; AlQuorain H; Murshed M; Rauch F
Pediatr Nephrol; 2020 Oct; 35(10):1843-1854. PubMed ID: 31392510
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries.
Al Juraibah F; Al Amiri E; Al Dubayee M; Al Jubeh J; Al Kandari H; Al Sagheir A; Al Shaikh A; Beshyah SA; Deeb A; Habeb A; Mustafa M; Zidan H; Mughal MZ
Arch Osteoporos; 2021 Mar; 16(1):52. PubMed ID: 33660084
[TBL] [Abstract][Full Text] [Related]
9. Hereditary hypophosphatemic rickets with hypercalciuria: a study for the phosphate transporter gene type IIc and osteoblastic function.
Yamamoto T; Michigami T; Aranami F; Segawa H; Yoh K; Nakajima S; Miyamoto K; Ozono K
J Bone Miner Metab; 2007; 25(6):407-13. PubMed ID: 17968493
[TBL] [Abstract][Full Text] [Related]
10. Early Discrimination Between Tumor-Induced Rickets/Osteomalacia and X-Linked Hypophosphatemia in Chinese Children and Adolescents: A Retrospective Case-Control Study.
Jiajue R; Ni X; Jin C; Huo L; Wu H; Liu Y; Jin J; Yu W; Lv W; Zhou L; Xia Y; Chi Y; Cui L; Pang Q; Li X; Jiang Y; Wang O; Li M; Xing X; Meng X; Xia W
J Bone Miner Res; 2021 Sep; 36(9):1739-1748. PubMed ID: 33971042
[TBL] [Abstract][Full Text] [Related]
11. Hypophosphatemic osteomalacia: a report of five cases and evaluation of bone markers.
Ros I; Alvarez L; Guañabens N; Peris P; Monegal A; Vázquez I; Cerdá D; Ballesta AM; Muñoz-Gómez J
J Bone Miner Metab; 2005; 23(3):266-9. PubMed ID: 15838631
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two assays for fibroblast growth factor (FGF)-23.
Ito N; Fukumoto S; Takeuchi Y; Yasuda T; Hasegawa Y; Takemoto F; Tajima T; Dobashi K; Yamazaki Y; Yamashita T; Fujita T
J Bone Miner Metab; 2005; 23(6):435-40. PubMed ID: 16261449
[TBL] [Abstract][Full Text] [Related]
13. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.
Imel EA; DiMeglio LA; Hui SL; Carpenter TO; Econs MJ
J Clin Endocrinol Metab; 2010 Apr; 95(4):1846-50. PubMed ID: 20157195
[TBL] [Abstract][Full Text] [Related]
14. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B
Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
[TBL] [Abstract][Full Text] [Related]
15. High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH.
Igaki JM; Yamada M; Yamazaki Y; Koto S; Izawa M; Ariyasu D; Suzuki E; Hasegawa H; Hasegawa Y
Endocr J; 2011; 58(8):647-55. PubMed ID: 21597229
[TBL] [Abstract][Full Text] [Related]
16. X-Linked Hypophosphatemic Rickets: Multisystemic Disorder in Children Requiring Multidisciplinary Management.
Baroncelli GI; Mora S
Front Endocrinol (Lausanne); 2021; 12():688309. PubMed ID: 34421819
[TBL] [Abstract][Full Text] [Related]
17. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.
Carpenter TO; Insogna KL; Zhang JH; Ellis B; Nieman S; Simpson C; Olear E; Gundberg CM
J Clin Endocrinol Metab; 2010 Nov; 95(11):E352-7. PubMed ID: 20685863
[TBL] [Abstract][Full Text] [Related]
18. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
Kinoshita Y; Fukumoto S
Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
[TBL] [Abstract][Full Text] [Related]
19. Serum 1,25-dihydroxyvitamin D levels in subjects with X-linked hypophosphatemic rickets and osteomalacia.
Lyles KW; Clark AG; Drezner MK
Calcif Tissue Int; 1982 Mar; 34(2):125-30. PubMed ID: 6282408
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1.
Hannan FM; Athanasou NA; Teh J; Gibbons CL; Shine B; Thakker RV
Eur J Endocrinol; 2008 Feb; 158(2):265-71. PubMed ID: 18230836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
